{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:58:43Z","timestamp":1769525923688,"version":"3.49.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Mast cell leukemia (MCL) is an extremely rare and aggressive hematologic malignancy, characterized by a poor prognosis and short survival. Currently, no standardized treatment guidelines have been established. This study presents the clinical data of a patient with primary MCL accompanied by C-findings, and analyzes the clinical features, diagnostic challenges, and therapeutic approaches for this disease through a comprehensive review of the relevant literature. Furthermore, the study discusses current perspectives on research developments in MCL. By increasing clinical awareness of MCL, this work aims to provide valuable insights and references for clinicians in the diagnosis and management of this challenging condition.<\/jats:p>","DOI":"10.3389\/fonc.2025.1537301","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:52:38Z","timestamp":1740466358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mast cell leukemia: a rare case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Lu","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaodan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry","volume":"7","author":"Kennedy","year":"2023","journal-title":"Blood Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v204.2","article-title":"Advanced systemic mastocytosis-Revised classification, new drugs and how we treat","volume":"204","author":"Pardanani","year":"2024","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.lrr.2020.100230","article-title":"Acute aleukemic mast cell leukemia: Report of a case and review of the literature","volume":"14","author":"Galura","year":"2020","journal-title":"Leuk Res Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardani","year":"2021","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","volume-title":"Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis withan associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation","year":"2024"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1537301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:52:40Z","timestamp":1740466360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1537301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":13,"alternative-id":["10.3389\/fonc.2025.1537301"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1537301","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1537301"}}